Skip to content

Study · Not a test of the peptide alone · 2026

12 results

HA/CD44-SS31 Mitochondrial Targeting of Manganese Oxide Nanozymes for Ischemia-Reperfusion-Induced Acute Kidney Injury Therapy.

Lin Z, Zhou E, Zhang D, Ke J, Wang Y, Zou X, Dong L, Wang R, Liu X, Wang Y

ACS nano6 Feb 2026Cited by 1 (Europe PMC)

PMID41649374 (opens in a new tab)DOI10.1021/acsnano.5c16933 (opens in a new tab)PepBankPUB-41649374
Publisher pagePubMedAsk about this study
Jump to 12 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study12

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone12

In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Elamipretide (SS-31).

  1. 01AnimalNot a test of Elamipretide (SS-31) aloneAnimal study (in vivo)Pharmacokinetics

    In a murine ischemia-reperfusion acute kidney injury model, HMN@HA-SS31 crossed the compromised filtration barrier and accumulated in damaged PTECs.

    In plain wordsIn mice with kidney injury, a nanoparticle carrying SS31 and other parts reached damaged kidney tube cells.

    Peptide
    Elamipretide (SS-31)
    Outcome
    Not applicableAccumulation in damaged proximal tubular cells
    Study

    mousen: not reported in source

    Murine I/R-AKI model
    Outcome group
    Pharmacokinetics · Kidney and urinary

    Source sentences

    Summary
    In a murine I/R-AKI model, HMN@HA-SS31 traversed the compromised filtration barrier, accumulated in damaged PTECs, reduced renal ROS, improved kidney function and histopathology, inhibited the cGAS-STING pathway, limited fibrosis under a multidose regimen, and increased 21-day survival to 80% withou…

    In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).

  2. 02AnimalNot a test of Elamipretide (SS-31) aloneAnimal study (in vivo)Mechanism

    In a murine ischemia-reperfusion acute kidney injury model, HMN@HA-SS31 reduced renal ROS.

    In plain wordsIn mice with kidney injury, a nanoparticle carrying SS31 and other parts lowered reactive oxygen species in the kidney.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreaseRenal ROS
    Study

    mousen: not reported in source

    Murine I/R-AKI model
    Outcome group
    Mitochondrial function · Kidney and urinary

    Source sentences

    Summary
    In a murine I/R-AKI model, HMN@HA-SS31 traversed the compromised filtration barrier, accumulated in damaged PTECs, reduced renal ROS, improved kidney function and histopathology, inhibited the cGAS-STING pathway, limited fibrosis under a multidose regimen, and increased 21-day survival to 80% withou…

    In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).

  3. 03AnimalNot a test of Elamipretide (SS-31) aloneAnimal study (in vivo)Efficacy outcome

    In a murine ischemia-reperfusion acute kidney injury model, HMN@HA-SS31 improved kidney function.

    In plain wordsIn mice with kidney injury, a nanoparticle carrying SS31 and other parts improved kidney function.

    Peptide
    Elamipretide (SS-31)
    Outcome
    Direction not reportedKidney function
    Study

    mousen: not reported in source

    Murine I/R-AKI model
    Outcome group
    Kidney function · Kidney and urinary

    Source sentences

    Summary
    In a murine I/R-AKI model, HMN@HA-SS31 traversed the compromised filtration barrier, accumulated in damaged PTECs, reduced renal ROS, improved kidney function and histopathology, inhibited the cGAS-STING pathway, limited fibrosis under a multidose regimen, and increased 21-day survival to 80% withou…

    In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).

  4. 04AnimalNot a test of Elamipretide (SS-31) aloneAnimal study (in vivo)Efficacy outcome

    In a murine ischemia-reperfusion acute kidney injury model, HMN@HA-SS31 improved kidney histopathology.

    In plain wordsIn mice with kidney injury, a nanoparticle carrying SS31 and other parts improved the look of kidney tissue under the microscope.

    Peptide
    Elamipretide (SS-31)
    Outcome
    Direction not reportedKidney histopathology
    Study

    mousen: not reported in source

    Murine I/R-AKI model
    Outcome group
    Kidney function · Kidney and urinary

    Source sentences

    Summary
    In a murine I/R-AKI model, HMN@HA-SS31 traversed the compromised filtration barrier, accumulated in damaged PTECs, reduced renal ROS, improved kidney function and histopathology, inhibited the cGAS-STING pathway, limited fibrosis under a multidose regimen, and increased 21-day survival to 80% withou…

    In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).

  5. 05AnimalNot a test of Elamipretide (SS-31) aloneAnimal study (in vivo)Mechanism

    In a murine ischemia-reperfusion acute kidney injury model, HMN@HA-SS31 inhibited the cGAS-STING pathway.

    In plain wordsIn mice with kidney injury, a nanoparticle carrying SS31 and other parts reduced activity of the cGAS-STING inflammation pathway.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreasecGAS-STING pathway activity
    Study

    mousen: not reported in source

    Murine I/R-AKI model
    Outcome group
    Inflammation markers · Kidney and urinary

    Source sentences

    Summary
    In a murine I/R-AKI model, HMN@HA-SS31 traversed the compromised filtration barrier, accumulated in damaged PTECs, reduced renal ROS, improved kidney function and histopathology, inhibited the cGAS-STING pathway, limited fibrosis under a multidose regimen, and increased 21-day survival to 80% withou…

    In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).

  6. 06AnimalNot a test of Elamipretide (SS-31) aloneAnimal study (in vivo)Efficacy outcome

    In a murine ischemia-reperfusion acute kidney injury model, HMN@HA-SS31 limited fibrosis under a multidose regimen.

    In plain wordsIn mice with kidney injury, a nanoparticle carrying SS31 and other parts limited scarring of the kidney after several doses.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreaseRenal fibrosis
    Study

    mousen: not reported in source

    Murine I/R-AKI model
    Outcome group
    Kidney function · Kidney and urinary

    Source sentences

    Summary
    In a murine I/R-AKI model, HMN@HA-SS31 traversed the compromised filtration barrier, accumulated in damaged PTECs, reduced renal ROS, improved kidney function and histopathology, inhibited the cGAS-STING pathway, limited fibrosis under a multidose regimen, and increased 21-day survival to 80% withou…

    In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).

  7. 07AnimalNot a test of Elamipretide (SS-31) aloneAnimal study (in vivo)Efficacy outcome

    In a murine ischemia-reperfusion acute kidney injury model, HMN@HA-SS31 increased 21-day survival to 80%.

    In plain wordsIn mice with kidney injury, a nanoparticle carrying SS31 and other parts raised 21-day survival to 80%.

    Peptide
    Elamipretide (SS-31)
    Outcome
    Increase21-day survival
    Study

    mousen: not reported in source

    Murine I/R-AKI model
    Outcome group
    Mortality · Kidney and urinary

    Measurements

    21-day survival
    80%
    HMN@HA-SS31

    Source sentences

    Summary
    In a murine I/R-AKI model, HMN@HA-SS31 traversed the compromised filtration barrier, accumulated in damaged PTECs, reduced renal ROS, improved kidney function and histopathology, inhibited the cGAS-STING pathway, limited fibrosis under a multidose regimen, and increased 21-day survival to 80% withou…

    In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).

  8. 08AnimalNot a test of Elamipretide (SS-31) aloneAnimal study (in vivo)Safety outcome

    In a murine ischemia-reperfusion acute kidney injury model, HMN@HA-SS31 showed no detectable toxicity.

    In plain wordsIn mice with kidney injury, a nanoparticle carrying SS31 and other parts caused no detectable toxicity.

    Peptide
    Elamipretide (SS-31)
    Outcome
    No significant changeToxicity
    Study

    mousen: not reported in source

    Murine I/R-AKI model
    Outcome group
    Adverse events · Kidney and urinary

    Source sentences

    Summary
    In a murine I/R-AKI model, HMN@HA-SS31 traversed the compromised filtration barrier, accumulated in damaged PTECs, reduced renal ROS, improved kidney function and histopathology, inhibited the cGAS-STING pathway, limited fibrosis under a multidose regimen, and increased 21-day survival to 80% withou…

    In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).

  9. 09LabNot a test of Elamipretide (SS-31) aloneIn vitro (cells)Mechanism

    In H2O2-challenged human kidney HK-2 cells, the nanozyme conjugate HMN@HA-SS31 reduced mitochondrial ROS.

    In plain wordsIn kidney cells, a nanoparticle carrying SS31 and other parts lowered mitochondrial reactive oxygen species.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreaseMitochondrial ROS in HK-2 cells
    Study

    humann: not reported in source

    H2O2-challenged HK-2 cells
    Outcome group
    Mitochondrial function · Kidney and urinary

    Source sentences

    Summary
    In H2O2-challenged human kidney (HK-2) cells, HMN@HA-SS31 reduced mtROS, restored membrane potential and network integrity, and significantly decreased apoptosis.

    In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).

  10. 10LabNot a test of Elamipretide (SS-31) aloneIn vitro (cells)Mechanism

    In H2O2-challenged human kidney HK-2 cells, the nanozyme conjugate HMN@HA-SS31 restored membrane potential and network integrity.

    In plain wordsIn kidney cells, a nanoparticle carrying SS31 and other parts restored the health of mitochondria after damage.

    Peptide
    Elamipretide (SS-31)
    Outcome
    IncreaseMitochondrial membrane potential and network integrity in HK-2 cells
    Study

    humann: not reported in source

    H2O2-challenged HK-2 cells
    Outcome group
    Mitochondrial function · Kidney and urinary

    Source sentences

    Summary
    In H2O2-challenged human kidney (HK-2) cells, HMN@HA-SS31 reduced mtROS, restored membrane potential and network integrity, and significantly decreased apoptosis.

    In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).

  11. 11LabNot a test of Elamipretide (SS-31) aloneIn vitro (cells)Efficacy outcome

    In H2O2-challenged human kidney HK-2 cells, the nanozyme conjugate HMN@HA-SS31 significantly decreased apoptosis.

    In plain wordsIn kidney cells, a nanoparticle carrying SS31 and other parts reduced cell death.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreaseApoptosis in HK-2 cells
    Study

    humann: not reported in source

    H2O2-challenged HK-2 cells
    Outcome group
    Kidney function · Kidney and urinary

    Source sentences

    Summary
    In H2O2-challenged human kidney (HK-2) cells, HMN@HA-SS31 reduced mtROS, restored membrane potential and network integrity, and significantly decreased apoptosis.

    In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).

  12. 12LabNot a test of Elamipretide (SS-31) aloneIn vitro (cell-free)Activity measurement

    The SS31-functionalized manganese oxide nanozyme HMN@HA-SS31 showed broad multi-ROS scavenging, with SOD-like and catalase-like activities.

    In plain wordsIn lab tests, a nanoparticle carrying SS31 and other parts removed several harmful reactive oxygen molecules.

    Peptide
    Elamipretide (SS-31)
    Outcome
    IncreaseROS scavenging catalytic activity
    Study

    n: not reported in source

    HMN@HA-SS31 nanozyme
    Outcome group
    Mitochondrial function · Kidney and urinary

    Source sentences

    Summary
    HMN@HA-SS31 was synthesized through templated shell growth and orthogonal ligations, resulting in broad multi-ROS scavenging capabilities with superoxide dismutase (SOD)- and catalase (CAT)-like activities, as well as preferential mitochondrial localization.

    In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 08:19 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:47 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.